This is a working overview of metabolic research, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-11. Anything still debated is marked as such rather than presented as settled.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Oral: Capsules: Prometrium (100 mg, 200 mg, 300 mg) Vaginal: Tablets: Endometrin (100 mg); Gels: Crinone (4%, 8%) Intramuscular injection: Oil: Progesterone (50 mg/mL) A 25 mg/mL concentration of progesterone oil for intramuscular injection and a 38 mg/device progesterone intrauterine device (Progestasert) have been discontinued. An oral combination formulation of micronized progesterone and estradiol in oil-filled capsules (brand name Bijuva) is marketed in the United States for the treatment of menopausal symptoms and endometrial hyperplasia. Progesterone is also available in unregulated custom preparations from compounding pharmacies in the United States. In addition, transdermal progesterone is available over-the-counter in the United States, although the clinical efficacy of transdermal progesterone is controversial.
=== March === 1 March – First Minister Humza Yousaf announces that his wife, Nadia El-Nakla, is expecting a baby in July, making him the first Scottish First Minister to become a parent while in office. 7 March – The Scottish Government announces an independent public inquiry into the police handling of the Emma Caldwell murder investigation. Police Scotland announces it will no longer investigate every low level crime following the success of a pilot project. 8 March – The creators of Wirdle, a Shetland dialect version of the Wordle game, announce the game's withdrawal following legal threats from The New York Times, owners of the original game. 9 March – A Daily Telegraph report alleging a conflict-of-interest involving First Minister Humza Yousaf after the Scottish Government donated £250,000 to the UN agency UNRWA, which supports Palestinian refugees, is rejected by Yousaf as an "outrageous smear" and a "far right conspiracy". 10 March – The Duke of Edinburgh is awarded the Order of the Thistle by Charles III, Scotland's highest royal honour. Creative Scotland launches an investigation into a decision to provide nearly £85,000 of public money for an arts project involving "hardcore" sex performances. 11 March – The driver of a double decker bus is arrested after the vehicle's roof is ripped off after crashing into a railway bridge in West Lothian. No passengers were aboard the bus at the time. 12 March – Professor Jason Leitch announces he will leave his role as National Clinical Director at the end of April.
Colombian literature dates back to pre-Columbian era; a notable example of the period is the epic poem known as the Legend of Yurupary. In Spanish colonial times, notable writers include Juan de Castellanos (Elegías de varones ilustres de Indias), Hernando Domínguez Camargo and his epic poem to San Ignacio de Loyola, Pedro Simón and Juan Rodríguez Freyle. Post-independence literature linked to Romanticism highlighted Antonio Nariño, José Fernández Madrid, Camilo Torres Tenorio and Francisco Antonio Zea. In the second half of the nineteenth century and early twentieth century the literary genre known as costumbrismo became popular; great writers of this period were Tomás Carrasquilla, Jorge Isaacs and Rafael Pombo (the latter of whom wrote notable works of children's literature). Within that period, authors such as José Asunción Silva, José Eustasio Rivera, León de Greiff, Porfirio Barba-Jacob and José María Vargas Vila developed the modernist movement. In 1872, Colombia established the Colombian Academy of Language, the first Spanish language academy in the Americas. Candelario Obeso wrote the groundbreaking Cantos Populares de mi Tierra (1877), the first book of poetry by an Afro-Colombian author. Between 1939 and 1940 seven books of poetry were published under the name Stone and Sky in the city of Bogotá that significantly influenced the country; they were edited by the poet Jorge Rojas.
Sources: en.wikipedia.org
As no American president had ever visited Moscow before, Kissinger got the impression that Brezhnev wanted the planned summit to happen "at almost any cost". Despite Nixon's orders, Kissinger was rather emollient with Brezhnev, and though Nixon's instructions stated that he was only to discuss Vietnam, he began to talk about arms control instead. Kissinger informed Brezhnev that the United States wanted all of the PAVN divisions taking part in the present offensive to return to North Vietnam at once, a "demand" that many historians argue was, in fact, a disguised concession, as Kissinger only mentioned the divisions sent south for the Easter Offensive, presumably meaning that the PAVN divisions who had arrived before the Easter Offensive could stay, thus abandoning the "mutual withdrawal formula" that Tho had rejected out of hand so many times. Kissinger, in his memoirs, called this claim "pure nonsense", but Tho, at the time, interpreted Kissinger's statement to Brezhnev in those terms. Kissinger reportedly considered his demand that the three PAVN divisions engaged in the Easter Offensive to be a "throwaway" as he did not expect North Vietnam to pull any troops out of South Vietnam. Upon his return to Washington, Kissinger reported that Brezhnev would not cancel the summit and was keen to sign the SALT I Treaty.
== Role in cancer == Studies indicate significant HB-EGF gene expression elevation in a number of human cancers as well as cancer-derived cell lines. Evidence indicates that HB-EGF plays a significant role in the development of malignant phenotypes contributing to the metastatic and invasive behaviors of tumors. The proliferative and chemotactic effects of HB-EGF results from the target influence on particular cells including fibroblasts, smooth muscles cells, and keratinocytes. For numerous cell types such as breast and ovarian tumor cells, human epithelial cells and keratinocytes HB-EGF is a potent mitogen resulting in evidenced upregulation of HB-EGF in such specimens. Both in vivo and in vitro studies of tumor formation in cancer derived cell lines indicate that expression of HB-EGF is essential for tumor development. As a result, studies implementing the use of specific HB-EGF inhibitors and monoclonal antibodies against HB-EGF show the potential for the development of novel therapies for treating cancers by targeting HB-EGF expression.
=== NADPH === NADPH is produced from NADP+. The major source of NADPH in animals and other non-photosynthetic organisms is the pentose phosphate pathway, by glucose-6-phosphate dehydrogenase (G6PDH) in the first step. The pentose phosphate pathway also produces pentose, another important part of NAD(P)H, from glucose. Some bacteria also use G6PDH for the Entner–Doudoroff pathway, but NADPH production remains the same. Ferredoxin–NADP+ reductase, present in all domains of life, is a major source of NADPH in photosynthetic organisms including plants and cyanobacteria. It appears in the last step of the electron chain of the light reactions of photosynthesis. It is used as reducing power for the biosynthetic reactions in the Calvin cycle to assimilate carbon dioxide and help turn the carbon dioxide into glucose. It has functions in accepting electrons in other non-photosynthetic pathways as well: it is needed in the reduction of nitrate into ammonia for plant assimilation in nitrogen cycle and in the production of oils. There are several other lesser-known mechanisms of generating NADPH, all of which depend on the presence of mitochondria in eukaryotes. The key enzymes in these carbon-metabolism-related processes are NADP-linked isoforms of malic enzyme, isocitrate dehydrogenase (IDH), and glutamate dehydrogenase. In these reactions, NADP+ acts like NAD+ in other enzymes as an oxidizing agent. The isocitrate dehydrogenase mechanism appears to be the major source of NADPH in fat and possibly also liver cells. These processes are also found in bacteria.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.